

HENRY FORD HEALTH INSTITUTIONAL BIOSAFETY COMMITTEE (IBC) MEETING



Board Meetings: Quarterly
Quorum = 5

Friday, May 22, 2026

MEMBER ATTENDANCE:

PRESENT	ABSENT	MEMBER NAME	DEGREE EARNED	AREA OF SPECIALTY	DEPARTMENT	AFFILIATE OF HFH?
V		Wilson, George (C)	PhD	Biomedical/Radiobiology	Research Administration	Yes
	X	Palanisamy, Nallasivam (VC)	PhD	Genomics Technology	Urology	Yes
V		Baker, Kevin C.	PhD	Animals	Bone and Joint	Yes
V		Bobbitt, Kevin	PhD	Viral Immunology	Public Health Services	Yes
V		Hay, Nancy	MHSA	Community Interest	Non-Affiliated	No
V		Liu, Xianshuang	PhD	Gene Therapy	Neurology	Yes
	X	Notebaert, Andrea	BS	Animals	Bioresources	Yes
V		Nyati, Shyam	PhD	Gene Therapy	Radiation Oncology	Yes
	X	Ramesh, Mayur	MD	Human Clinical Trials	Infectious Disease	Yes
V		Swiecki, Mark	BS	Community Interest	Non-Affiliated	No

IBC Quorum Rules: The National Institutes of Health (NIH) Guidelines, which govern recombinant and synthetic nucleic acid research, do not explicitly define a quorum for an IBC; however, HFH IBC considers a quorum to be a majority of the total voting membership (50% of the membership for the year plus one).

CONSULTANTS/INVITED GUESTS:

PRESENT	NAME	DEGREE/S EARNED	ROLE	AFFILIATED W/ HFH?
	Combs, Lena	BS, MJ	Research Administration	Yes
	Eliya, Sonia	PharmD	Research Pharmacy	Yes
	Pabla, Pardeep	PharmD	Research Pharmacy	Yes
V	Raju, Vivek	MS	Research Administration	Yes
	Trancik, Emily	PhD	Ethics	Yes
	White, Mary Jo	MBA	Compliance	Yes
V	Hughes, Jennifer	BS	Research Administration	Yes

Others Present may include regularly attending consultants, IBC administrative staff and representatives of the HFH Office of General Counsel. Consultants/Staff are not members of the IBC and shall not vote. However, they must disclose any conflicts of interest. During this meeting, staff or consultants may be called upon to provide advice or counsel to the IBC concerning study activities.

Presiding: George Wilson, Ph.D., Chair

Recording: Minutes for this meeting were recorded by Jennifer Hughes, Senior Coordinator of Research Compliance.

1.0 GENERAL INFORMATION

1.1 QUORUM AND CALL TO ORDER

The Chair of the meeting verified that quorum requirements were met. The meeting was called to order at 2:02 PM with 6 of 10 members present. The meeting was conducted via video conferencing, and it was confirmed that all present members were able to participate in the discussion. All IBC members and consultants received access to all pertinent materials for review prior to the meeting.

1.2 REVIEW OF PREVIOUS MEETING MINUTES

The meeting minutes from the previous IBC meeting on March 20, 2026 were provided to all the attendees prior to the meeting for review. The minutes were voted on and approved by the committee.

APPROVED: Minutes were approved				
TOTAL MEMBERS VOTING	# FOR	# AGAINST	# ABSTAINED	# RECUSAL(S)
6	6	0	0	0

2.0 PROTOCOL REVIEW REPORT

- 2.1 RENEWALS:** 1
- 2.2 MODIFICATIONS:** 0
- 2.3 CLOSED:** 3
- 2.4 EXPIDITED:** 1

3.0 REVIEW OF PROTOCOLS

3.1 EXPEDITED:

██████████ from Neurology Research submitted an application similar to 2026.06 and works in ██████████ group. Same model for Multiple Sclerosis (MS) using pertussis toxin.

X. Liu joined meeting at 2:05pm changing the voting number from 6 to 7 out of 10.

PI had time constraints for approval.

3.2 MODIFICATION:

Dr. Qing-Sheng Mi Dermatology Research submitted a modification.
G. Wilson communicated with IACUC Chair and Attending Veterinarian (AV). The modification had a different rational and methodology. IBC is requesting a new protocol.

Event Type	Agenda #	Reviewers	PI	Protocol #	Protocol Title:
-------------------	-----------------	------------------	-----------	-------------------	------------------------

PURPOSE: Experimental autoimmune encephalitis (EAE) is a well-known animal model of Multiple sclerosis (MS). These are useful models to understand the mechanism of MS disease progression and widely used to test possible therapy for MS. Here, we will examine the role of various genes in the pathogenic / protective role in MS pathogenesis using animal models of MS. [REDACTED] will induce EAE disease in various genetically modified mice with background of C57B6 mice and examine how these genes play role in either protective or pathogenic role in EAE. To induce EAE, C57B6 mice will be given intraperitoneal (i.p.) injection of pertussis toxin (PT, 200ng/mouse, twice) in the volume of 100ul. Without PT treatment, animals do not show clinical symptoms and EAE disease cannot be induced.

Training: Complete for all study members listed.

REVIEWER PRESENTATION AND DISCUSSION:

- Scientific member provided an overview of the submission.
- Proper personal protection equipment (PPE) details noted.
- Scientific member motioned to withhold pending response to the requested changes.

ACTION TAKEN BY IBC: Withhold. The IBC action was taken pursuant to a motion made by the reviewer of this study which was seconded by another IBC Committee member:

Withhold Approval: The protocol will need to be resubmitted with the following requested changes to be reviewed via expedited procedures by a Committee member:

- There is a new Biosafety cabinet available for use. Update details.
- How will the toxin be moved from the laboratory to the Bioresources facility?

TOTAL MEMBERS VOTING	# FOR	# AGAINST	# ABSTAINED	# RECUSAL(S)
7	7	0	0	0

4.0 ROUNDTABLE DISCUSSION

4.1 MRSA

HFH has an incident of MRSA use in a laboratory without IBC oversight.

5.0 MEETING ADJOURNMENT

The meeting was adjourned at 2:38 pm.

Meeting minutes respectfully submitted by Jennifer Hughes, BS.